(Date:7/2/2009)...SNewswire/ -- Pro-life forces won an important bat... uphold a state law regulating that abortion cente...ering RU-486 (also known as the "abortion pill") i...rug. , , The ruling came in Rogers v. Planned... a 2004 law requiring that those administering RU-...
(Date:7/2/2009)...sses honored in Washington, D.C. , , ARLINGTON... Health Resources has received the Best Employers...usiness Group on Health. , , (Logo: http://w... ) , , The award recognizes the nation,s leadi...te a healthy workplace and for helping employees a...
(Date:7/2/2009)...educe threat, expert says , , THURSDAY,...at to certain species of wildlife, which need to b... say. , "Cancer is one of the leading health co...cent of human deaths. But we now understand that c...d author Denise McAloose, chief pathologist for th...
(Date:7/2/2009)... set of neurons, another set wakes up: study , ... information about brain circuit activity may help...bien (zolpidem) walk, eat, talk on the phone and e...embering it the next morning. , The drug has al...ts into a conscious state. , In experiments wit...
Breaking Medicine News(10 mins):Health News:Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of 'Abortion Pill' 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3Health News:Cancer Endangers Some Wildlife Species 2Health News:Odd Behaviors on Ambien Linked to Brain Circuitry 2(Date:7/2/2009)...ATINE, Ill. and BRISTOL, Tenn., July 2 /PRNewswire...: ACUR ) and King Pharmaceuticals, Inc. (NYSE: ...Administration (FDA) has issued a Complete Respons...for Acurox (oxycodone HC1, USP and niacin, USP) Ta...or the relief of moderate-to-severe pain. , ,...
(Date:6/30/2009)...LOTHIAN, Va., June 30 In two recen... nebulizer and PRONEB compressors (Ultra and Ultra...umarate (Perforomist, DEY LP, Mylan Inc.) improves...researchers chose PARI products as the exclusive n...tenance treatments for COPD. Sutherland et al. us...
(Date:6/29/2009)...spective Study Seeks to Assess RSV Burden in Outpa...ng Commitment to Pediatric Research , , GAITH...ntinues to advance its commitment to pediatric res...vational prospective study designed to assess the ...preterm infants 32-to-35 weeks gestational age (GA...
(Date:6/28/2009)...HMOND, Calif., June 29 S...nnounced that a key research milestone has been ac...Genentech, Inc., a wholly-owned member of the Roch...el characteristics for pharmaceutical protein prod...inger DNA-binding protein nuclease (ZFN) technolog...
Breaking Medicine Technology:Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 2Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 3PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies 2MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday August 6 2008 After Close of U S Based Financial Markets 6836 1Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday August 6 2008 After Close of U S Based Financial Markets 6836 2InterMune to Present at BMO Healthcare Conference 6834 1Bioheart Inc Announces Financial Results for Second Quarter 2008 6832 1Bioheart Inc Announces Financial Results for Second Quarter 2008 6832 2Bioheart Inc Announces Financial Results for Second Quarter 2008 6832 3Bioheart Inc Announces Financial Results for Second Quarter 2008 6832 4Bioheart Inc Announces Financial Results for Second Quarter 2008 6832 5Bioheart Inc Announces Financial Results for Second Quarter 2008 6832 6Bioheart Inc Announces Financial Results for Second Quarter 2008 6832 7Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6830 1Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6830 2Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6830 3Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6830 4Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6830 5Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6830 6Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6830 7Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6830 8Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6830 9..., 2007 /PRNewswire-FirstCall/ -- Vion,Pharmaceutic...a in,a poster session at the 12th Congress of the ...ienna, Austria on its lead anticancer,agent Cloret...center international Phase II clinical trial in a ...leukemia (AML) or high-risk,myelodysplastic syndro...
...ESS WIRE)--Jun 11, 2007 - Geron,Corporation (Nasda...ch studies indicating that GRNOPC1, the company,s ... for the treatment of,spinal cord injury, evades a...ted by Geron scientist Ross Okamura at the Federat...n Diego, the findings,could mean that patients tre...
Other Medicine Technology:Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting 2Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting 3Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting 4Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3...n the way it implements the confocal principle, th...It allows multi fluorescence images to be collecte...Unprecedented flexibility for individual applicati...ions that guarantee fast and efficient structural ...
...esigned for system expandability: the first invert...e the infinity space. Multi-port design enables op... variety of illumination and detector equipment. E...s the addition of an optional light source and oth...
...olor video camera with direct digital output. Thre... fluorescence applications. Olympus wide array of ...image quality and flexibility you need for an effi...ide a high-resolution, real-time image of your spe...
...he PM30 is a premium photomicrography system that...hs of even the most difficult specimens. Designed ...e solution to the complex problem of fluorescence ...xposure control, the system utilizes special progr...
Medicine Products: